Welcome to our dedicated page for Cytodyn SEC filings (Ticker: CYDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CytoDyn Inc. (CYDY) SEC filings page on Stock Titan provides direct access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-assisted context. As a Delaware-incorporated, clinical-stage biotechnology and oncology company trading on the OTCQB, CytoDyn files a variety of documents that detail its clinical strategy, governance, capital structure, and material events.
Key filings for CYDY include current reports on Form 8‑K, which the company uses to report significant developments. Recent 8‑Ks describe an agreement in principle to settle a securities class action lawsuit, including the contemplated mix of cash and common stock, and a Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville) that outlines terms under which CytoDyn may sell common stock over a multi‑year period. Another 8‑K and related proxy materials document stockholder approval of an amendment to increase the total number of authorized shares of common stock and the filing of a corresponding Certificate of Amendment in Delaware.
CytoDyn’s definitive proxy statement on Schedule DEF 14A provides additional insight into corporate governance, annual meeting agendas, advisory votes on executive compensation, auditor selection, and proposals related to share authorization. The proxy statement also explains how the company solicits votes, conducts virtual stockholder meetings, and structures its board elections.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of each document, helping readers quickly understand complex legal and financial language. Real-time updates from EDGAR ensure that new 8‑Ks, proxy statements, and other reports appear promptly, while structured data makes it easier to track items such as amendments to the certificate of incorporation, equity financing arrangements, and outcomes of stockholder votes.
For investors analyzing CYDY, the SEC filings page is a primary source for understanding how CytoDyn manages its capital, responds to litigation, and formalizes decisions that affect shareholders, all grounded in the company’s official regulatory disclosures.
CytoDyn Inc. updates a prospectus supplement registering up to 375,999,668 shares of common stock for resale by selling stockholders. The supplement states this total comprises 181,324,099 shares offered directly and 194,675,569 shares underlying warrants.
The supplement incorporates a Form 8-K dated March 24, 2026, disclosing that the company extended two secured convertible promissory notes originally issued in 2021 by 36 months. As consideration, CytoDyn agreed to make monthly payments totalling $1,000,000 in shares (priced at the lower of the prior trading day close or a five-day average) through the new maturities in April 2029, and reduced the annual interest rate on each note to 5%.
CytoDyn Inc. director Tanya Durkee Urbach received a grant of non-qualified stock options covering 574,385 shares of common stock at an exercise price of $0.2800 per share. The grant was approved by the Compensation Committee on March 20, 2026, as her annual fiscal 2026 award under CytoDyn's 2012 Equity Incentive Plan.
The options vest in 12 approximately equal monthly installments from April 2026 through March 2027, contingent on continued service. Following this grant, Urbach holds stock options for 574,385 underlying shares directly.
CytoDyn Inc. director Stephen M. Simes received a grant of 574,385 non-qualified stock options to buy common stock at $0.28 per share. The award was approved on March 20, 2026 as his regular annual grant under CytoDyn’s 2012 Equity Incentive Plan.
The options expire on March 20, 2036 and vest in 12 approximately equal monthly installments from April 2026 through March 2027, contingent on his continued service. Following this grant, Simes holds 574,385 derivative securities representing the right to acquire the same number of common shares.
CytoDyn Inc. director Lishomwa C. Ndhlovu received a non-qualified stock option grant covering 574,385 shares of common stock at an exercise price of $0.28 per share. The option expires on March 20, 2036 and was approved as the annual grant for fiscal year 2026 under CytoDyn's 2012 Equity Incentive Plan.
The award vests in 12 approximately equal monthly installments for continuous service from April 2026 through March 2027. After this grant, Ndhlovu holds stock options for 574,385 shares directly.
CytoDyn Inc. reported that Chief Executive Officer Jacob P. Lalezari received a grant of non-qualified stock options for 4,874,691.0000 shares of common stock at an exercise price of $0.2800 per share as his annual fiscal 2026 award under the 2012 Equity Incentive Plan.
According to the vesting schedule, 1,218,672 underlying shares will vest on March 20, 2027, with the remaining options vesting in approximately equal monthly installments from April 2027 through March 2030, subject to continuous service. This is a compensation-related, non-market transaction.
CytoDyn Inc. reported that Chief Financial Officer Robert E. Hoffman received a grant of non-qualified stock options covering 4,874,691 shares of common stock. The options have an exercise price of $0.28 per share and expire on March 20, 2036.
This award represents his annual equity grant for fiscal year 2026 under CytoDyn's 2012 Equity Incentive Plan. Vesting is time-based: 1,218,672 shares vest on March 20, 2027, with the remaining options vesting in approximately equal monthly installments from April 2027 through March 2030, contingent on continued service.
CytoDyn Inc. director Dunlap Ryan reported receiving a grant of non-qualified stock options to buy 574,385 shares of common stock. The options have an exercise price of $0.28 per share and expire in March 2036. This award represents his annual fiscal 2026 grant under CytoDyn's 2012 Equity Incentive Plan.
The options vest in 12 approximately equal monthly installments from April 2026 through March 2027, conditioned on continued service. After this grant, Ryan holds 574,385 derivative securities, and the filing does not show any open-market purchases or sales of CytoDyn common stock.
CytoDyn Inc. director Karen J. Brunke received a grant of non-qualified stock options covering 574,385 shares of common stock. The options have an exercise price of $0.28 per share and were approved as her annual fiscal 2026 grant under CytoDyn's 2012 Equity Incentive Plan.
The award vests in 12 approximately equal monthly installments from April 2026 through March 2027, subject to continuous service. Following this grant, Brunke holds 574,385 derivative securities in the form of these options directly.
CytoDyn Inc. reported that Chief Legal Officer Tyler Blok received a grant of non-qualified stock options as part of his fiscal 2026 compensation. The award covers 3,249,794 options to buy common stock at an exercise price of $0.28 per share, expiring in 2036.
The grant was approved by the Compensation Committee on March 20, 2026 under CytoDyn’s 2012 Equity Incentive Plan. 812,448 underlying shares will vest on March 20, 2027, with the remaining options vesting in roughly equal monthly installments from April 2027 through March 2030, subject to continuous service.
CytoDyn Inc. amended two secured convertible promissory notes originally issued in April 2021, each with an initial principal amount of $28.5 million. On March 24, 2026, the company and the noteholders agreed to extend the maturity dates of these notes by 36 months to April 5, 2029 and April 23, 2029, respectively.
As consideration for the extensions, CytoDyn will make combined monthly payments valued at $1,000,000 in shares of common stock through the new maturity dates, with the share value based on the lower of the prior day’s closing price or the average closing price over the previous five trading days. The annual interest rate on each note was reduced to 5%, lowering the cash interest burden while committing to ongoing equity-based payments.